Observational studies suggest a potential link between GLP-1 drugs, such as Ozempic, and reduced incidence of certain cancers. However, experts caution against interpreting these findings as proof of cancer prevention. The observed lower cancer rates may be attributed to “healthy-user bias,” where individuals taking these medications are generally more health-conscious and engage in preventative behaviors. Currently, the follow-up periods in these studies are relatively short, limiting the ability to draw definitive conclusions about long-term cancer prevention. Further research is needed to determine if Ozempic itself has a protective effect, or if the association is due to other factors. While promising, the current evidence does not support the claim that Ozempic can prevent cancer. Misinterpreting headlines on this topic is easy, and a cautious approach is warranted.